ライフサイエンスコーパス: cord blood transplantation

1 ion for non-malignant diseases-for umbilical cord blood transplantation.

2 CD34(+)/CD38(-)/CD90(+)/CD45RA(+) HSCs after cord blood transplantation.

3 leted bone marrow or unmanipulated umbilical cord blood transplantation.

4 s may have clinical application in marrow or cord blood transplantation.

5 given single-unit, unrelated donor umbilical cord blood transplantation.

6 gressed to phase 1 clinical trials in double cord blood transplantation.

7 d the delayed platelet engraftment following cord blood transplantation.

8 eformed DSAs on outcomes in double umbilical cord blood transplantation.

9 ot been well defined for unrelated umbilical-cord blood transplantation.

10 alignancies undergoing unrelated double unit cord blood transplantation.

11 with the Rac2 mutation underwent successful cord blood transplantation.

12 t after autologous, allogeneic and umbilical cord blood transplantation.

13 hromatic leukodystrophy treated by umbilical cord blood transplantation.

14 chronic myelogenous leukemia after umbilical cord blood transplantation.

15 phoid recovery are the 2 major challenges in cord blood transplantation.

16 to increasing homing and engraftment during cord blood transplantation.

17 nt and survival in unrelated donor umbilical cord blood transplantation.

18 nd have the potential for immunotherapy post cord blood transplantation.

19 doses restricts the usefulness of umbilical-cord-blood transplantation.

20 interaction on leukaemia-free survival after cord-blood transplantation.

21 chronic GVHD was more likely to occur after cord-blood transplantation.

22 delay of functional B cells associated with cord blood transplantations.

23 (111 patients) or single-unit (113 patients) cord-blood transplantation after a uniform myeloablative

24 rine model for human placental and umbilical cord blood transplantation and second to evaluate the en

25 nts with Hurler syndrome underwent umbilical cord blood transplantation and were evaluated at baselin

26 e marrow failure that occurs after umbilical cord blood transplantation and with aplastic anemia, res

27 rved in the setting of immune recovery after cord blood transplantation, and may be associated with i

28 ntions, such as hydroxyurea; bone marrow and cord blood transplantation; and improvements in supporti

29 Two critical concerns in clinical cord blood transplantation are the initial time to engra

30 chromatic leukodystrophy underwent umbilical cord blood transplantation at different stages of diseas

31 There were no differences in outcome after cord-blood transplantation between patients with one HLA

32 ce graft-versus-host disease after umbilical cord blood transplantation, but this naivety and their l

33 uence NK cell reconstitution after umbilical cord blood transplantation by accelerating the different

34 Hematopoietic stem cell and umbilical cord blood transplantation can be a life-saving procedur

35 Dramatic advances in cord blood transplantation (CBT) have been made in the p

36 ective study of T-cell immune recovery after cord blood transplantation (CBT) in a predominantly adul

37 While cord blood transplantation (CBT) is an effective therapy

38 Delayed myeloid engraftment after cord blood transplantation (CBT) is thought to result fr

39 summarizes the current status of double-unit cord blood transplantation (CBT) to improve engraftment,

40 The ability of cord blood transplantation (CBT) to prevent relapse depe

41 Unrelated cord blood transplantation (CBT) without in vivo T-cell

42 In cord blood transplantation (CBT), donor-directed host an

43 Delayed engraftment is a major limitation of cord blood transplantation (CBT), due in part to a defec

44 of autoimmune diseases (ADs) occurring after cord blood transplantation (CBT), we analyzed both CBT r

45 maternal HLA antigens (NIMA) and double-unit cord blood transplantation (CBT).

46 it in 14 patients who received a double-unit cord blood transplantation (CBT).

47 d with improved outcomes following pediatric cord blood transplantation (CBT).

48 isease (SCD) receiving HLA-identical sibling cord blood transplantation (CBT, n = 96) or bone marrow

49 eneic cell transplantation [ACT]; n = 18) or cord blood transplantation (CBT; n = 16).

50 immune response on outcomes after unrelated cord blood transplantations (CBTs).

51 Double-unit cord blood transplantation (DCBT) appears to enhance eng

52 In adults, umbilical cord blood transplantation, double umbilical cord blood

53 Although double umbilical cord blood transplantation (dUCBT) in adult patients may

54 reactivity is favored after double umbilical cord blood transplantation (dUCBT) in which cord blood (

55 Cord-blood transplantation favorably altered the natural

56 od grafts can be used as an animal model for cord blood transplantation for gene therapy studies wher

57 atching who received a single unit umbilical cord blood transplantation for non-malignant diseases re

58 HLA matching on outcomes of single umbilical-cord blood transplantations for leukaemia and myelodyspl

59 h hematological malignancies given umbilical cord blood transplantation from donors carrying a homozy

60 Unrelated donor cord blood transplantation from partially HLA-mismatched

61 Umbilical cord blood transplantation from unrelated donors has bee

62 transplant-related mortality after umbilical-cord-blood transplantation, greater investment in large-

63 Although cord blood transplantation has significantly extended th

64 The results for adult umbilical cord blood transplantation have improved, with greater e

65 ents undergoing T-cell-depleted or unrelated cord blood transplantation have undetectable EBV-specifi

66 More than 4000 cord blood transplantations have been performed worldwid

67 re similar after single-unit and double-unit cord-blood transplantation; however, a single-unit cord-

68 Outcomes of unrelated donor cord blood transplantation in 191 hematologic malignancy

69 e the first report of a successful umbilical cord blood transplantation in 1988, there has been great

70 Data regarding the outcome of cord-blood transplantation in adults are scant, despite

71 Umbilical cord blood transplantation is associated with durable en

72 Cord blood transplantation is now an established field w

73 A major area of concern for the use of cord blood transplantation is the delay in myeloid and l

74 Umbilical cord blood transplantation may cure a relevant proportio

75 studies suggested that allogeneic umbilical cord blood transplantation may potentially emerge as the

76 tigations include MSC infusions in umbilical cord blood transplantation, MSC therapy for tissue regen

77 cyte antigen-matched sibling donor umbilical cord blood transplantation, or 0-2 human leukocyte antig

78 sociated with HHV-6 DNAemia were as follows: cord blood transplantation (P<0.001), conditioning regim

79 The literature shows that after umbilical cord blood transplantation the relapse rate, disease-fre

80 In umbilical cord blood transplantation, the ability to find adequate

81 HHV-6B) commonly reactivates after umbilical cord blood transplantation (UCBT) and is associated with

82 ntation (MMRDT) or unrelated-donor umbilical cord blood transplantation (UCBT) are valuable treatment

83 (n = 226) or double-unit (n = 435) unrelated cord blood transplantation (UCBT) following a reduced-in

84 f the art of unrelated donor (URD) umbilical cord blood transplantation (UCBT) for the treatment of h

85 Umbilical cord blood transplantation (UCBT) is an expanding practi

86 Unrelated cord blood transplantation (UCBT) is associated with del

87 Umbilical cord blood transplantation (UCBT) is increasingly used a

88 A disadvantage of umbilical cord blood transplantation (UCBT) is the delay in immune

89 stitution observed after unrelated umbilical cord blood transplantation (UCBT).

90 morbidity and mortality following umbilical cord blood transplantation (UCBT).

91 variella volvacea following double umbilical cord blood transplantation (UCBT).

92 GVHD) occurs less frequently after umbilical cord blood transplantation (UCBT).

93 ctive single-center analysis of 50 umbilical cord blood transplantations UCBTs performed from 2001 to

94 including 37 single and 13 double umbilical cord blood transplantations UCBTs.

95 engraftment after unrelated donor umbilical cord blood transplantation was 100% with no patient havi

96 Initially, umbilical cord blood transplantation was limited to children, give

97 w outlines the state of the art of umbilical cord blood transplantation, with emphasis on practical c